New data from Phase III EMILIA study showed Roche’s trastuzumab emtansine (T-DM1) significantly improved survival of people with HER2-positive metastatic breast cancer
27 August 2012 | By Roche
Pivotal study met co-primary efficacy endpoint of overall survival...